💉
Tirzepatide (Mounjaro, Zepbound)
GLP-1 receptor agonists — Living Evidence Monitor
Data last updated 11 studies cited
How this page is produced
Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This is an AI-assisted evidence summary, not a clinician endorsement and not medical advice. Read how we build and check these pages.
KEY FINDINGS
Rate of proactive dose reduction of concomitant hypoglycemia-inducing medications by physicians
39.2%
Source [1] · DOI ·
All-cause mortality with incretin-based therapy vs SGLT2i in AF/HFpEF patients at 1 year
HR 0.721
95% CI: 0.634-0.820
Source [2] · DOI ·
Inpatient visits with incretin-based therapy vs SGLT2i in AF/HFpEF patients
HR 0.743
95% CI: 0.702-0.787
Source [2] · DOI ·
Pulmonary embolism risk with tirzepatide vs. lifestyle intervention
HR 0.258
95% CI: 0.222-0.299
Source [3] · DOI ·
Pulmonary embolism risk with tirzepatide vs. lifestyle intervention
RR 0.215
95% CI: 0.185-0.250
Source [3] · DOI ·
Deep vein thrombosis risk with tirzepatide vs. lifestyle intervention
HR 0.361
95% CI: 0.322-0.406
Source [3] · DOI ·
Deep vein thrombosis risk with tirzepatide vs. lifestyle intervention
RR 0.303
95% CI: 0.270-0.340
Source [3] · DOI ·
Major adverse cardiovascular events vs GLP-1 receptor agonists
HR 0.75
95% CI: , 0.63-0.91
Source [4] · DOI ·
Tirzepatide 15 mg or maximum tolerated dose in adults with obesity without diabetes
18.04% greater reduction in body weight versus placebo; p<0.00001
95% CI: -19.86 to -16.22
Source [6] · DOI ·
Exploratory indirect comparison of percentage weight loss across Asian and predominantly non-Asian trial populations; the analysis cannot establish equivalence
-18.16% in Asian trials versus -17.92% in predominantly non-Asian trials; p=0.94
Source [6] · DOI ·
At 1 year, tirzepatide was associated with lower heart failure risk than semaglutide among patients with type 2 diabetes.
RR 0.82
95% CI: 0.78-0.86
Source [7] · DOI ·
At 1 year, tirzepatide was associated with lower heart failure risk than semaglutide among patients without diabetes.
RR 0.60
95% CI: 0.55-0.65
Source [7] · DOI ·
Reported 1-year heart failure risk difference favoring tirzepatide over semaglutide among patients with type 2 diabetes.
1.5% risk difference
Source [7] · DOI ·
Reported 1-year heart failure risk difference favoring tirzepatide over semaglutide among patients without diabetes.
0.9% risk difference
Source [7] · DOI ·
Significant effect modification by diabetes status for atrial fibrillation at 1 year.
P = 0.003
Source [7] · DOI ·
Significant effect modification by diabetes status for heart failure at 1 year.
P < 0.001
Source [7] · DOI ·
Significant effect modification by diabetes status for acute myocardial infarction at 1 year.
P = 0.019
Source [7] · DOI ·
Heart failure events within 1 year among patients with obesity initiating tirzepatide after TAVR versus matched patients not receiving tirzepatide
HR 0.68
95% CI: 0.56-0.83
Source [8] · DOI ·
Acute kidney injury within 1 year among patients with obesity initiating tirzepatide after TAVR versus matched patients not receiving tirzepatide
HR 0.63
95% CI: 0.43-0.93
Source [8] · DOI ·
No statistically significant association with acute myocardial infarction within 1 year after TAVR
HR 0.81
95% CI: 0.48-1.37
Source [8] · DOI ·
No statistically significant difference in fall events, the prespecified falsification endpoint
HR 0.82
95% CI: 0.47-1.43
Source [8] · DOI ·
Adjusted relative likelihood of achieving at least 15% weight loss with tirzepatide versus liraglutide among adults with obesity; observational analysis with possible residual confounding, a tirzepatide sample of 386, and limited follow-up.
aHR 5.57
95% CI: 3.66-8.49
Source [9] · DOI ·
Mean weight change at 12 months among tirzepatide initiators with obesity; observational analysis with possible residual confounding, a tirzepatide sample of 386, and limited follow-up.
-13.0%
Source [9] · DOI ·
MACE with tirzepatide versus placebo in the principal frequentist network meta-analysis of randomized trials lasting at least 40 weeks
OR 0.82
95% CI: 0.72-0.93
Source [10] · DOI ·
All-cause mortality with tirzepatide versus placebo in the principal frequentist network meta-analysis of randomized trials lasting at least 40 weeks
OR 0.72
95% CI: 0.64-0.82
Source [10] · DOI ·
Mean percentage body weight regain after tirzepatide cessation in the drug-class subgroup meta-analysis (k = 3); overall heterogeneity was high (I² = 97.6%).
13.04%
95% CI: 11.87-14.21
Source [11] · DOI ·
SOURCES
- [1]Kitsunai, Hiroya et al.. Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.. Endocrine journal. 2026. DOI (opens in new tab)
- [2]Ahmed, Faizan et al.. GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.. Journal of clinical medicine. 2026. DOI (opens in new tab)
- [3]Kahkedjian, Fredy et al.. Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.. Frontiers in endocrinology. 2026. DOI (opens in new tab)
- [4]Wu, Jheng-Yan et al.. Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. Journal of the American Heart Association. 2026. DOI (opens in new tab)
- [5]Zeng, Lijuan et al.. Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.. Annals of the American Thoracic Society. 2026. DOI (opens in new tab)
View all 11 cited studiesShow fewer sources
- [6]Kamrul-Hasan, A B M et al.. Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026. DOI (opens in new tab)
- [7]Azzam, Ahmed Y et al.. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. 2026. DOI (opens in new tab)
- [8]Mortada, Ibrahim et al.. Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.. Journal of the Society for Cardiovascular Angiography & Interventions. 2026. DOI (opens in new tab)
- [9]Hwang, Inyoung et al.. Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.. Drug design, development and therapy. 2026. DOI (opens in new tab)
- [10]Silverii, Giovanni Antonio et al.. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.. Diabetes, obesity & metabolism. 2026. DOI (opens in new tab)
- [11]Patel, Henna et al.. Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.. Cureus. 2026. DOI (opens in new tab)
Get an email when this evidence changes
ModernDoc will email you when a validated finding on this page is added or corrected — nothing else, no marketing. There is no fixed schedule: if the evidence doesn't change, we don't email.
We'll first send one confirmation email — you're not subscribed until you click it. Subscribing signals an interest in GLP-1 receptor agonists; we treat that as sensitive: we store only your email address and this topic, never linked to any health record, and never shared or sold. Every email includes a one-click unsubscribe link. Sent by ModernDoc (moderndoc.co).
See a problem with the Tirzepatide (Mounjaro, Zepbound) evidence?
Send a source correction or freshness concern. We cannot provide personal medical advice through this site.
Report a correction